JP2023549703A5 - - Google Patents

Info

Publication number
JP2023549703A5
JP2023549703A5 JP2023526258A JP2023526258A JP2023549703A5 JP 2023549703 A5 JP2023549703 A5 JP 2023549703A5 JP 2023526258 A JP2023526258 A JP 2023526258A JP 2023526258 A JP2023526258 A JP 2023526258A JP 2023549703 A5 JP2023549703 A5 JP 2023549703A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
product according
diabetes
alkoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023526258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549703A (ja
JP7909312B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/060045 external-priority patent/WO2022091029A1/en
Publication of JP2023549703A publication Critical patent/JP2023549703A/ja
Publication of JP2023549703A5 publication Critical patent/JP2023549703A5/ja
Application granted granted Critical
Publication of JP7909312B2 publication Critical patent/JP7909312B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023526258A 2020-10-30 2021-10-29 BETブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体2阻害剤の組み合わせを用いてHbA1cを低下させるための方法 Active JP7909312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107843P 2020-10-30 2020-10-30
US63/107,843 2020-10-30
PCT/IB2021/060045 WO2022091029A1 (en) 2020-10-30 2021-10-29 Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (3)

Publication Number Publication Date
JP2023549703A JP2023549703A (ja) 2023-11-29
JP2023549703A5 true JP2023549703A5 (cg-RX-API-DMAC10.html) 2024-10-31
JP7909312B2 JP7909312B2 (ja) 2026-08-21

Family

ID=

Similar Documents

Publication Publication Date Title
JP7069253B2 (ja) 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン
US20190381045A1 (en) Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
JP4664505B2 (ja) ビュープロピオン代謝物質ならびにその合成方法および使用
EP3092231B1 (en) Sgc stimulators
CN103945848A (zh) 被取代的喹唑啉酮的口服即释制剂
JP7202892B2 (ja) 非アルコール性脂肪性肝疾患の予防及び治療薬
US10647679B2 (en) N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
US20260027088A1 (en) Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer
JP2002536410A (ja) 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用
JP2023500685A5 (cg-RX-API-DMAC10.html)
JP2023547475A5 (cg-RX-API-DMAC10.html)
JP5680412B2 (ja) レオヌリンの使用およびその組成物
CN110891942B (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
EP3858351B1 (en) Tolperisone and eperisone for use in the treatment of pulmonary fibrosis
US20240277722A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
JP2015524474A (ja) 治療レジメン
JP2023509186A5 (cg-RX-API-DMAC10.html)
JP2026510456A (ja) Ampk活性化および/またはchop阻害により処置できる疾患および障害の処置のためのセフィン1および関連化合物
JP2014509643A (ja) 黄斑変性の予防または治療用の医薬組成物
CN101128418A (zh) 4-羟基异亮氨酸的非对映异构体及其用途
US20070010541A1 (en) Methods for treating vascular diseases
KR102947841B1 (ko) 대사 장애 치료를 위한 벤즈이미다졸 화합물
JP2003500353A (ja) 処置方法
JP2024042690A (ja) 非アルコール性脂肪性肝疾患の予防及び/又は治療薬